Paul Romness Discusses OS Therapies' IPO & Clinical Advancement

Proactive - Interviews for investors

OS Therapies CEO Paul Romness joined Steve Darling from Proactive to share news the company has been accepted into Johnson & Johnson Innovation – JLABS, a prestigious platform that supports innovation in the life sciences sector. Through this membership, OS Therapies aims to advance its tunable Antibody Drug Conjugate (ADC) linker-based platform into clinical development. This platform utilizes pH-sensitive linkers and coating technology designed to reduce off-target effects, thereby improving safety and increasing the number and diversity of therapeutic payloads that can be delivered. The tunable ADC platform being developed by OS Therapies holds the promise of offering enhanced efficacy compared to other ADCs currently available or in development. The drug candidates produced using this platform benefit from a unique linker technology, creating new intellectual property for both novel and off-patent targeting antibodies and drug payloads. In addition to this significant milestone, Romness announced that OS Therapies has added Dr. Borys Shor, PhD, to its Antibody Drug Conjugate Advisory Board. Dr. Shor brings over 20 years of experience in oncology discovery programs, particularly in leading preclinical discovery and development efforts for small molecule kinase inhibitors, biologics, and nanoparticles at major pharmaceutical and biotech companies. In his advisory role, Dr. Shor will guide OS Therapies in selecting the most appropriate antibodies and payloads for development using the company's proprietary pH-sensitive SiLinker™ silicone linker technology. These strategic advancements mark a pivotal moment for OS Therapies as it moves closer to bringing innovative and effective cancer therapies to the market. #proactiveinvestors #ostherapies #nyseamerican #ostx #pharma #Immunotherapy #CancerResearch #BiotechIPO #CancerTreatment #Osteosarcoma #BiotechInnovation #PaulRomness #ADCtechnology #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews